Examkin

Question

Difficulty: HardPharmacologic Interventions

A 48-year-old woman comes to the clinic reporting persistently low mood, anhedonia, fatigue, and difficulty concentrating for the past three months. She states she has been struggling emotionally since completing local radiation therapy for early-stage, estrogen receptor-positive breast cancer six months ago. She has been taking tamoxifen daily since that time. In addition to her mood symptoms, she complains of severe, frequent hot flashes that wake her up multiple times a night, resulting in significant daytime sleepiness. Her vital signs are temperature 37.0°C (98.6°F), blood pressure 122/78 mm Hg, and pulse 74/min. Physical examination is unremarkable. The physician diagnoses her with major depressive disorder and discusses treatment options to manage her current symptoms. Which of the following is the most appropriate pharmacologic intervention?

  1. VenlafaxineAnswer
  2. B
    Paroxetine
  3. C
    Fluoxetine
  4. D
    Bupropion
  5. E
    Clonidine

Answer

The most appropriate pharmacologic intervention is venlafaxine, as it treats both depression and hot flashes without inhibiting the CYP2D6-mediated activation of tamoxifen.
Venlafaxine is the most appropriate pharmacologic intervention because it effectively treats both major depressive disorder and vasomotor symptoms (hot flashes) without significantly interfering with the metabolism of tamoxifen. Tamoxifen is a prodrug that must be converted to its active metabolite, endoxifen, primarily by the hepatic cytochrome P450 2D6 (CYP2D6) enzyme. Unlike many other antidepressants, venlafaxine is only a weak inhibitor of CYP2D6, allowing tamoxifen to retain its antineoplastic efficacy.

Step-by-Step Solution

1
Analyze the patient's presenting symptoms and medical history.
The patient has new-onset major depressive disorder and severe vasomotor symptoms (hot flashes), alongside a history of ER-positive breast cancer currently managed with tamoxifen.
Establishing all active clinical issues ensures that the chosen intervention addresses both symptom clusters safely.
2
Evaluate the pharmacokinetic properties of the patient's current medications.
Tamoxifen is a prodrug that requires activation into its potent metabolite, endoxifen, by the hepatic cytochrome P450 enzyme CYP2D6.
Understanding the metabolism of current medications is crucial for preventing adverse drug-drug interactions that could compromise cancer treatment.
3
Assess the pharmacological profiles of the available treatment options for depression and hot flashes.
Paroxetine, fluoxetine, and bupropion are potent CYP2D6 inhibitors. Venlafaxine is a weak inhibitor that effectively treats both depression and hot flashes.
Strong CYP2D6 inhibitors prevent the formation of endoxifen, decreasing tamoxifen's efficacy and increasing the risk of breast cancer recurrence.
4
Select the optimal pharmacologic intervention.
Venlafaxine is selected as the safest and most effective therapy.
It successfully treats both the psychiatric and vasomotor symptoms without compromising the antineoplastic effects of tamoxifen.

Key Concept

In patients taking tamoxifen for breast cancer, strong CYP2D6 inhibitors (such as paroxetine, fluoxetine, and bupropion) must be avoided to prevent therapeutic failure; SNRIs with minimal CYP2D6 inhibition, like venlafaxine, are the preferred treatment for concurrent depression and hot flashes.
Estimated Time:1m 15s
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic